Patent Docs: Sanofi-Aventis Loses Patent Infringement Suit against Amphastar and Teva

Authors

Contributors

About the Authors

The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Juristat #4 Overall Rank

E-mail Newsletter

Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Subscribe to this blog's feed

Contact the Docs

[email protected]

Foreign Correspondents

Disclaimer

"Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Juristat #8 Overall Rank

« Virus for Sale | Main | Postscript: When Flu Is for Sale, Who Should Pay? »

February 09, 2007

Sanofi-Aventis Loses Patent Infringement Suit against Amphastar and Teva

By Christopher P. Singer

Sanofi_aventis In a February 9, 2007 press release, Sanofi-Aventis announced that it has lost its patent infringement suit against generic drugmakers Amphastar Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd., filed in the U.S. District Court for the Central District of California. The suit relates to Sanofi-Aventis' blockbuster blood thinning drug, Lovenox®, which is covered by patent until February 2012. According to its press release, Sanofi-Aventis is considering its legal options going forward. The company also notes that while a number of manufacturers have requested FDA approval of purported generic versions of Lovenox®, the FDA has yet to approve any such request.